Donald C. Lo is an associate professor in the Department of Neurobiology at Duke University Medical Center and has been engaged in drug discovery and development for neurodegenerative disorders and stroke for more than 12 years. In 1997, he cofounded and was chief scientific officer of the biotechnology company Cogent Neuroscience, which developed neurogenomic approaches to new drug and drug target discovery in stroke, Huntington’s disease, and Alzheimer’s disease, the latter two indications in joint ventures with Elan Pharmaceuticals. In 2002, Lo established the Center for Drug Discovery (CDD) at Duke, for which he currently serves as director. The Duke CDD pursues multiple neurological drug discovery and development programs in collaboration with major pharmaceutical firms, biotechnology companies, and nonprofit disease research foundations, with its major focus on Huntington’s disease.

Robert E. Hughes is an assistant professor at the Buck Institute for Age Research in Novato, California. He has been actively engaged in Huntington’s disease research for more than 10 years in both academia and the biotechnology industry. From 2002–2007, Hughes served on the scientific advisory board of the Hereditary Disease Foundation. Before joining the Buck Institute, he worked at Myriad Proteomics (later Prolexys Pharmaceuticals), where he directed a bioinformatics group and a Huntington’s disease target discovery program. Currently, Dr. Hughes’s laboratory has a major emphasis on the discovery and validation of novel targets in Huntington’s disease and other age-related diseases.